Keltic Pharma Therapeutics

Today we are at the #ScotLifeSci24 conference talking about innovation and globalisation in the life sciences industry in Scotland. With a target of £35BN by 2035 there is a huge amount of innovation coming through the life sciences eco system. Keltic Pharma are proud to play our part. Some fascinating insights from Richard Lochhead including the work being done at our ‘home’ in the University of Glasgow Advanced Research Centre.

One minute he’s our superstar CSO and the next he’s a radio legend. Andrew Jamieson had his debut on radio earlier today 👇🏻📻🎤

Andrew Tobin was kindly invited to India and has been introduced to some amazing people doing great things by Kiran Mazumdar Shaw. Lovely to hear about them.

Keltic Pharma is delighted to be a major contributor to the discovery that covalent inhibitors against PfCLK3, the target for our Bill & Melinda Gates Foundation funded radical cure for malaria, might provide an answer to a single dose cure for malaria. Skye Brettell and Professor Andrew Jamieson have made a significant breakthrough.

Andrew Jamieson ‘s latest publication has gone live. 👏🏻👏🏻

We are looking for a post-doctoral research associate to work on our Wellcome Trust funded addiction programme looking for novel ways of combating the opioid crisis. The research will be conducted @University of Glasgow Advanced Research Centre (ARC) @University of Glasgow in close collaboration with Dr Carrie Jones @Warren Centre for Neuroscience Drug Discovery @Vanderbilt University. This post, will investigate molecular mechanisms that can prevent opioid misuse and opioid-use-disorder and hence have a major impact on the global opioid crisis. In exciting breakthrough studies, we have discovered that inhibition of the M5 muscarinic acetylcholine receptor (M5-receptor) can prevent opioid drug seeking and reduce cue-induced relapse. The implications of our findings are huge. They indicate that by co-administration of a drug that inhibits the M5-receptor with opioid analgesics we can reduce the likelihood of patients becoming addicted to opioids and for those patients in remission from opioid addiction we can reduce the likelihood of relapse. This project will work in close collaboration with leading in vivo pharmacologist Dr. Carrie Jones, Vanderbilt University, Nashville USA, to understand fundamental aspects of M5-receptor biology and optimise ligands that can modulate M5-receptor activity to reduce the risk of opioid-addiction whilst retaining the drug’s analgesic properties. As part of a multi-disciplinary team, you will generate novel genetically engineered mice that will be used in combination with unique tool ligands in conjunction with anatomical, behavioural and molecular biology-based studies to explore how M5-receptors regulate reward-seek pathways associated with drug-addiction and validate the potential of this G protein-coupled receptor (GPCR) as a therapeutic target. This is an opportunity for a highly motivated Research Scientist to conduct basic research with potential for pre-clinical translation. The candidate will be responsible for mapping the neuroanatomy of M5-receptor in the brain, pharmacological characterisation and in vitro and in vivo testing of novel agonists/ antagonists to M5-receptor and pre-clinical addiction studies to validate the M5-receptor as a target in the treatment of addiction. The candidate will be based at University of Glasgow in state-of-the-art laboratories located in the newly built Advanced Research Centre (ARC) in the heart of the University campus and have the opportunity to spend time in our collaborator’s lab in Nashville, Tennessee. Informal enquiries may be directed to Professor Andrew Tobin, Andrew.Tobin@glasgow.ac.uk This post is full time and has funding until 30th September 2029 To apply online at: https://lnkd.in/gESncnt9

As we say goodbye to the lovely Abbey who heads off to do her PhD (two desk away!), we wish her all the luck and thank her for the amazing work she has done at Keltic Pharma Therapeutics ❤️ #teamwork

🌟 Meet Our CSO, Professor Andrew Jamieson. 🌟 We are thrilled to announce that Keltic Pharma has been awarded a SMART Grant by Innovate UK to advance our innovative drug discovery platform, PEPSMOL©. This funding is a testament to our team’s dedication to pioneering new treatments for diseases that have been historically difficult to target. At Keltic Pharma, we're driven by scientific excellence and innovation and we’d like to introduce you to our Chief Scientific Officer, Professor Andrew Jamieson A founder of Keltic Pharma Therapeutics and a driving force behind our proprietary PEPSMOL© platform. Andrew brings a wealth of expertise in synthetic organic chemistry and peptide-based drug discovery, which is crucial to the ground-breaking work we're doing. Oh - and he also enjoys the odd glass of champagne when a celebration is in order 😀 With a distinguished career spanning over 20 years in both academia and industry, his work focuses on integrating the principles of synthetic chemistry and peptide engineering to create synthetic biologics, a new class of molecules that combine the best properties of small molecules and biologics like antibodies. Our initial focus with the PEPSMOL© platform is on inflammatory airway diseases, such as severe asthma that doesn’t respond to current treatments. The Keltic Pharma team have already validated the FFA4 receptor as a novel target in inflammatory lung disease, demonstrating the promise of our synthetic biologics approach in preclinical models. “With this SMART Grant, we can further validate the PEPSMOL© platform and explore new ways to treat severe asthma,” says Andrew. “We’re committed to leveraging our deep expertise in peptide chemistry and drug discovery to develop inhaled synthetic biologic drugs that offer new hope for patients.” Follow us for more updates as we continue to innovate and transform the future of drug discovery! 🌟 #Leadership #Biotech #Innovation #DrugDiscovery #SyntheticBiologics #GPCRs #Healthcare #SMARTGrant #InnovateUK #AsthmaTreatment #MedicalResearch #LifeSciences #KelticPharma #UniversityofGlasgow #AndrewJamieson

🚀 The good news keeps rolling! Keltic Pharma, a spin-out from the University of Glasgow, has been awarded a SMART Grant by Innovate UK! 🚀 Founded by Andrew Tobin, Andrew Jamieson, and Graeme Milligan, Keltic Pharma Therapeutics are thrilled to receive this recognition and support for our work on the PEPSMOL© Discovery Platform. This innovative approach targets previously hard-to-drug G protein-coupled receptors (GPCRs), with an initial focus on the FFA4 receptor. With this funding, we'll be advancing our development of synthetic biologics—a new class of molecules that blend the best properties of small molecules and biologics like antibodies. Our initial focus is on tackling severe asthma, a condition unresponsive to current treatments, by developing inhaled agents to normalise lung function and reduce inflammation. The SMART Grant enables us to expand our team in Glasgow, validate the platform, and drive forward our mission to bring new, effective treatments to patients and push the boundaries of biotech innovation in the UK. Follow us for more updates as we move forward on this exciting journey! 🌟 #SMARTGrant #InnovateUK #Biotech #Innovation #DrugDiscovery #Asthma #GPCR

🏆 Andrew Jamieson gave his CBBG Award lecture this weekend and was presented with the RSC Chemical Biology and Bio-organic Lectureship prize. 🏆 Congratulations Andrew - the team are delighted for you! 🍾🍾